EMFAT
MDGL icon

Emerald Mutual Fund Advisers Trust’s Madrigal Pharmaceuticals MDGL Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,500
Closed -$8.64M – 213
2026
Q1 		$8.64M Sell
16,500
-8,496
-34% -$4.06M 0.42% 90
2025
Q4 		$14.6M Sell
24,996
-10,095
-29% -$5.16M 0.71% 62
2025
Q3 		$16.1M Sell
35,091
-1,829
-5% -$682K 0.83% 46
2025
Q2 		$11.2M Buy
36,920
+1,682
+5% +$501K 0.68% 54
2025
Q1 		$11.7M Buy
35,238
+16,582
+89% +$5.45M 0.83% 46
2024
Q4 		$5.76M Sell
18,656
-3,031
-14% -$853K 0.35% 86
2024
Q3 		$4.6M Sell
21,687
-54,072
-71% -$13.8M 0.24% 106
2024
Q2 		$21.2M Hold
75,759
– – 1.11% 35
2024
Q1 		$20.2M Buy
75,759
+36,479
+93% +$8.6M 1.05% 34
2023
Q4 		$9.09M Buy
+39,280
New +$6.87M 0.48% 83
2023
Q3 		– Sell
-50,073
Closed -$11.6M – 246
2023
Q2 		$11.6M Sell
50,073
-16,125
-24% -$4.37M 0.63% 75
2023
Q1 		$16M Buy
66,198
+55,729
+532% +$15.2M 0.95% 40
2022
Q4 		$3.04M Buy
+10,469
New +$1.02M 0.19% 115

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's MDGL Position: Q2 2026 in Review

Emerald Mutual Fund Advisers Trust sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 16,500 shares — an estimated $8.64M sold.

Emerald Mutual Fund Advisers Trust first reported a position in MDGL in Q4 2022 and held it in 13 quarters. The position peaked at $21.2M in Q2 2024. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Emerald Mutual Fund Advisers Trust reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Emerald Mutual Fund Advisers Trust sold 16,500 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $8.64M.
  • Emerald Mutual Fund Advisers Trust first reported a position in Madrigal Pharmaceuticals in Q4 2022 and held it in 13 quarters.
  • Emerald Mutual Fund Advisers Trust's Madrigal Pharmaceuticals position peaked at $21.2M in Q2 2024.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q2 2026, filed 5 Aug 2026.